Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient

Inclusion Criteria: * HBV patients who have positive HBeAg or HBeAb * Must be healthy males or females between 18 to 60 years old * Must have a body mass index (BMI) of 18 to 30 kg/m2 * HBV DNA≥2000 IU/mL * ALT≥1.3 ULN and ≤10 ULN Exclusion Criteria: * Administrated a nucleoside analogues (acid) or interferons against hepatitis B virus drugs, immunosuppressants, immune regulator before 6 months;Or any other against hepatitis b virus therapy at the same time. * Participated in other clinical trials within a month. * Allergic to interferon. * T-Bil ≥2 ULN. ALB\<35g/L. PT≥4s. * Positive HCV-Ab,HEV-Ab,EBV-Ab,CMV-Ab,TPPA,HIV-Ab. * Organ transplant patients, except cornea or hair transplantation. * Other hepatopathy exclude NAFLD . * Drug addiction or alcohol dependence. * Malignancy(except cured cervical carcinoma in situ, BCC, squamous cell carcinoma) except liver history. * Serious retinal disease. * Active hemorrhagic disease or severe hematopoietic dysfunction or blood coagulation disorder. * Autoimmune disease. * Uncontrolled diabetes or thyroid disease or beyond grade 2 blood pressure. * WBC\<3×109/L or ANC\<1.5 ×109/L or PLT\<90 ×109/L or HGB\<ULN. * HCC or AFP\>100ng/mL. * Chronic kidney disease or sCr\>ULN. * Lactating women or pregnancy. * Cardiovascular and cerebrovascular events within 6 months. * Neurological or psychiatric disease or family history.